The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.
about
Cardiovascular abnormalities in autosomal-dominant polycystic kidney diseaseThe HALT polycystic kidney disease trials: design and implementation.Hypertension in autosomal dominant polycystic kidney disease.Novel targets for the treatment of autosomal dominant polycystic kidney disease.Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy.Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark.Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science PerspectiveADPKD: Prototype of Cardiorenal Syndrome Type 4Leveraging practice-based research networks to accelerate implementation and diffusion of chronic kidney disease guidelines in primary care practices: a prospective cohort study.Cyclic AMP-mediated cyst expansionMolecular pathways and therapies in autosomal-dominant polycystic kidney diseasePulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trialPolycystic liver and kidney diseases.Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model.Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring.Which antihypertensive drugs are the most nephroprotective and why?Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies.Feline CKD: New horizons - where do we go from here?New options in the treatment of autosomal dominant polycystic kidney disease.The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.Insights into autosomal dominant polycystic kidney disease by quantitative mass spectrometry-based proteomics.Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.Different regional dynamics of end-stage renal disease in Japan by different causes.Geographic differences in the increasing ESRD rate have disappeared in Japan.Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience.Prevention of apoptosis averts glomerular tubular disconnection and podocyte loss in proteinuric kidney disease.Pathways, perspectives and pursuits in polycystic kidney disease.Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.
P2860
Q24657714-7D36BF49-3A9A-4882-9300-D818AEEE89FEQ33571347-0B262FF9-7FAA-4EE3-8B76-63914080EE57Q33754691-D1DD17B9-6C0B-475B-B329-54DFB500C496Q33816594-9E831390-AC4F-4B44-9099-FCE4817F05BFQ34183178-BFA32CFF-489F-427B-8A23-F76A6F48FAC7Q34405449-439FF466-FF41-448E-A9ED-7067FEC2FF94Q34431996-2F0BA982-AFB0-468A-9B9E-81E6E57BF707Q34475590-D095B90B-E511-4D1A-A8F2-890666F03332Q34579290-ABD8C517-664F-47B4-981F-8AC3A83A8983Q34850793-6C8708AD-7AFF-43E6-8ADF-1D1B79B289A3Q35578646-495025A5-241C-40B3-B301-F23FC67A2201Q35579142-CA8B11A6-6B73-41FD-904E-BBC30DD9A377Q36336546-16B1AEBF-B295-447D-A9C5-61A944A72716Q36385359-B3EA1666-F5B1-4B4C-BA80-6EA56F8F9149Q36874564-1B082942-8286-4CFD-9BEF-6D2C3DEB496EQ37154147-05F6C739-916F-4862-8D00-9FF99B395D40Q37803235-8D4D1191-4B90-4170-9535-EE3905282BA9Q38063460-B2206EB1-A61B-4EE8-A7F4-08A7A2DD4B84Q38133700-BFE944D7-4B42-4AB9-8D3E-68073A7A0FEFQ38356125-A15160B9-DF30-44D1-9A1D-184908534B09Q38795233-7C354213-1628-40B2-A8D8-8612235B3913Q39255681-C1AE8A0A-29AE-4EB6-9726-23EE5FAD0A67Q47742358-517BD48C-E4FE-4472-A14E-9EA30164CA2EQ50684605-CE1FDAF6-FBEE-4714-A115-D168467EC018Q50767866-2A471F1F-D6D8-44BA-97D0-6E489F30776DQ51164793-DDA34B6C-5163-4C2B-9777-268F2616DBBAQ51302011-0BF76AC6-D44E-4FE1-BE5B-9DE429DA0ED8Q53093579-0B025348-5FBE-4C4F-A0ED-02589F7CA427Q53958174-B9A51884-55F4-4BDA-AD35-5ADE9CD9DF21Q54540098-81788040-BF46-49BD-8E4B-D4ADE0981F4B
P2860
The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The effect of angiotensin-conv ...... ced polycystic kidney disease.
@en
The effect of angiotensin-conv ...... ced polycystic kidney disease.
@nl
type
label
The effect of angiotensin-conv ...... ced polycystic kidney disease.
@en
The effect of angiotensin-conv ...... ced polycystic kidney disease.
@nl
prefLabel
The effect of angiotensin-conv ...... ced polycystic kidney disease.
@en
The effect of angiotensin-conv ...... ced polycystic kidney disease.
@nl
P2093
P1433
P1476
The effect of angiotensin-conv ...... ced polycystic kidney disease.
@en
P2093
ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group
Andrew S Levey
Anne-Lise Kamper
Gavin Becker
Giuseppe Maschio
Paul C Stark
Ronald D Perrone
Svend Strandgaard
Tazeen H Jafar
P304
P356
10.1111/J.1523-1755.2005.00077.X
P407
P577
2005-01-01T00:00:00Z
P5875
P6179
1043306318